Clinical Trial Update: A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab [Phase 1]

View source ↗

Summary

Phase 1 study of PF-05082566 as a single agent and with rituximab in various lymphomas; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Lymphoma Follicular
• Lymphoma Large B-cell Diffuse
• Non-hodgkin Lymphoma

Drugs mentioned

• PF-05082566 (4-1BB agonist)
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Status: COMPLETED | Results posted: 2020-03-17